Hyaluronic Acid Hydrogel Implants for Sustained Release of Oxaliplatin and Resiquimod to Prevent Hepatocellular Carcinoma Recurrence Post-Radiofrequency Ablation.

While a slight increase in initial drug release was observed, the differences did not reach statistical significance ( P > 0.05, Figure S8 , Supporting Information), indicating that the hydrogel has not yet been found to be enzyme‐responsive.To assess the systemic biocompatibility of BI, blood cell counts were measured on days 3 and 9 post‐injection.

also in 111,027 other papers